IL140926A0 - Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions - Google Patents

Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions

Info

Publication number
IL140926A0
IL140926A0 IL14092699A IL14092699A IL140926A0 IL 140926 A0 IL140926 A0 IL 140926A0 IL 14092699 A IL14092699 A IL 14092699A IL 14092699 A IL14092699 A IL 14092699A IL 140926 A0 IL140926 A0 IL 140926A0
Authority
IL
Israel
Prior art keywords
inflammatory
treatment
recombinant human
fibrotic conditions
human uteroglobin
Prior art date
Application number
IL14092699A
Other languages
English (en)
Original Assignee
Claragen Inc
Nat Inst Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Claragen Inc, Nat Inst Health filed Critical Claragen Inc
Publication of IL140926A0 publication Critical patent/IL140926A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
IL14092699A 1998-07-21 1999-07-19 Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions IL140926A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/120,264 US20020160948A1 (en) 1998-07-21 1998-07-21 Recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
PCT/US1999/016312 WO2000004863A2 (en) 1998-07-21 1999-07-19 Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions

Publications (1)

Publication Number Publication Date
IL140926A0 true IL140926A0 (en) 2002-02-10

Family

ID=22389207

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14092699A IL140926A0 (en) 1998-07-21 1999-07-19 Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions

Country Status (10)

Country Link
US (1) US20020160948A1 (xx)
EP (1) EP1100524A4 (xx)
JP (1) JP2002521316A (xx)
KR (1) KR20010085294A (xx)
CN (1) CN1323216A (xx)
AU (1) AU5112499A (xx)
BR (1) BR9912279A (xx)
CA (1) CA2338299A1 (xx)
IL (1) IL140926A0 (xx)
WO (1) WO2000004863A2 (xx)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122344B2 (en) * 1997-05-28 2006-10-17 Claragen, Inc. Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions
US20060025348A1 (en) * 1997-05-28 2006-02-02 Pilon Aprile L Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
US20060281681A1 (en) * 1997-05-28 2006-12-14 Pilon Aprile L Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease
AU5836700A (en) * 1999-06-01 2000-12-18 Patrick T. Prendergast Peptides for therapeutic use
US20040153073A1 (en) 2000-02-01 2004-08-05 Hand Innovations, Inc. Orthopedic fixation system including plate element with threaded holes having divergent axes
CN1315370A (zh) * 2000-03-27 2001-10-03 上海博德基因开发有限公司 一种新的多肽——人子宫珠蛋白11和编码这种多肽的多核苷酸
AU2000243657A1 (en) * 2000-04-21 2001-11-07 George Washington University Method of binding integrin for treatment of cancer
CN1323824A (zh) * 2000-05-16 2001-11-28 上海博德基因开发有限公司 一种新的多肽——人子宫珠蛋白9和编码这种多肽的多核苷酸
KR20110014199A (ko) * 2008-05-13 2011-02-10 클라라산스, 인크. 비강 비염 치료용 재조합 인간 ｃｃ10 및 이의 조성물
US8293101B2 (en) 2009-03-13 2012-10-23 Terrasep, Llc Methods and apparatus for centrifugal liquid chromatography
SG10201401194VA (en) 2009-07-27 2014-07-30 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
WO2011047065A1 (en) 2009-10-15 2011-04-21 Clarassance, Inc. Recombinant human cc10 protein for treatment of influenza
US9168285B2 (en) 2009-10-15 2015-10-27 Therabron Therapeutics, Inc. Recombinant human CC10 protein for treatment of influenza and ebola
EP2531208A4 (en) * 2010-02-03 2013-07-03 Univ Rochester TREATMENT OF FIBROSIS RELATED DISORDERS USING FIBRONECTIN BINDING PROTEINS AND POLYPEPTIDES
WO2019176866A1 (ja) * 2018-03-12 2019-09-19 国立研究開発法人医薬基盤・健康・栄養研究所 ウテログロビンを構造基盤とする二重特異性ポリペプチド

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696092A (en) * 1995-03-07 1997-12-09 George Washington University Methods and compositions for inhibiting metastasis of epithelial cell-derived cancers
US5935860A (en) * 1995-03-07 1999-08-10 The George Washington University Use of uteroglobin expression as a molecular marker for prostatic intraepithelial neoplasia
JP4400934B2 (ja) * 1996-08-19 2010-01-20 アボット・ラボラトリーズ 胸部の疾患の検出に有用な試薬及び方法

Also Published As

Publication number Publication date
WO2000004863A2 (en) 2000-02-03
KR20010085294A (ko) 2001-09-07
CN1323216A (zh) 2001-11-21
EP1100524A4 (en) 2003-08-27
EP1100524A2 (en) 2001-05-23
WO2000004863A3 (en) 2000-11-23
BR9912279A (pt) 2002-01-02
JP2002521316A (ja) 2002-07-16
US20020160948A1 (en) 2002-10-31
AU5112499A (en) 2000-02-14
CA2338299A1 (en) 2000-02-03

Similar Documents

Publication Publication Date Title
IL140926A0 (en) Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
AU1166502A (en) Human ect2 and methods of use
NZ314903A (en) A peg-ifn alpha conjugate and its use in the treatment of immunomodulatory disorders
HK1050126A1 (zh) 治療人食管異常組織的方法和系統
HUP0103236A2 (hu) Bőr- és szövetápoló és/vagy kezelő készítmény
EP0924983A4 (en) S (-) - TOLTERODINE FOR THE TREATMENT OF URINARY AND GASTROINTESTINAL DISORDERS
IL187512A0 (en) Use of (s,s)-reboxetine in the treatment of pain conditions and incontinence
EP1049457A4 (en) TREATMENT OF INFLAMMATORY SKIN DISEASES WITH BIOACTIVE GLASS
HUP0203367A3 (en) Benzylidine-thiazolidinediones and analogues and their use in the treatment of diabetes
HUP9904361A3 (en) Use of isobutylgaba and its derivatives for the treatment of pain
PL331708A1 (en) Treatment of common cold and allergic rhinitis
GB2314273B (en) The use of TCET in the prophylaxis and treatment of allergies
GB2317182B (en) Sulfated polysaccharides and uses thereof in medical treatment
IL139589A0 (en) Use of cyclosporins in the treatment of inflammatory autoimmune diseases
PT946175E (pt) Utilizacao de uma combinacao de inibidores de h+, k+ -atpase e de glucocorticiodes no tratamento de polipos nasais
PL352333A1 (en) Dihydrobenzodiazepines and use of same in treatment of dislipidemia
GB9912159D0 (en) Improvements in and relating to the treatment of water
IL147716A0 (en) Highly purified cytokine activating factor and methods of use
EP1085906A4 (en) ANTIBODIES AGAINST CYTOKINS FOR THE PREVENTION AND TREATMENT OF INFLAMMABLE INTESTINAL DISEASES
GB9912639D0 (en) Improvements in and relating to treatment of respiratory conditions
GB9911772D0 (en) Diagnosis and treatment of atherosclerosis
EP1161451A4 (en) HUMAN ALPHA ENDOKIN AND METHOD FOR ITS USE
GB9922752D0 (en) Medical devices and treatment and prophylaxis
AU2002300876A1 (en) Use of Recombinant Human Uteroglobin in Treatment of Inflammatory and Fibrotic Conditions
GB9811347D0 (en) Improvements in or relating diagnosis and treatment of bacterial infections